AU2001255524A1 - Compositions and methods for the therapy and diagnosis of acne vulgaris - Google Patents

Compositions and methods for the therapy and diagnosis of acne vulgaris

Info

Publication number
AU2001255524A1
AU2001255524A1 AU2001255524A AU5552401A AU2001255524A1 AU 2001255524 A1 AU2001255524 A1 AU 2001255524A1 AU 2001255524 A AU2001255524 A AU 2001255524A AU 5552401 A AU5552401 A AU 5552401A AU 2001255524 A1 AU2001255524 A1 AU 2001255524A1
Authority
AU
Australia
Prior art keywords
diagnosis
therapy
compositions
methods
acne vulgaris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255524A
Inventor
Ajay Bhatia
Darrick Carter
Shyian Jen
Jean-Francois L'maisonneuve
Jennifer L. Mitcham
David H Persing
Yasir A.W. Skeiky
Siqing Steven Wang
Yanni Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2001255524A1 publication Critical patent/AU2001255524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001255524A 2000-04-21 2001-04-20 Compositions and methods for the therapy and diagnosis of acne vulgaris Abandoned AU2001255524A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19904700P 2000-04-21 2000-04-21
US60/199,047 2000-04-21
US20884100P 2000-06-02 2000-06-02
US60/208,841 2000-06-02
US21674700P 2000-07-07 2000-07-07
US60/216,747 2000-07-07
PCT/US2001/012865 WO2001081581A2 (en) 2000-04-21 2001-04-20 Compositions and methods for the therapy and diagnosis of acne vulgaris

Publications (1)

Publication Number Publication Date
AU2001255524A1 true AU2001255524A1 (en) 2001-11-07

Family

ID=27393973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255524A Abandoned AU2001255524A1 (en) 2000-04-21 2001-04-20 Compositions and methods for the therapy and diagnosis of acne vulgaris

Country Status (5)

Country Link
EP (1) EP1278854A2 (en)
JP (1) JP2004520803A (en)
AU (1) AU2001255524A1 (en)
CA (1) CA2407352A1 (en)
WO (1) WO2001081581A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2270030E (en) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Heterologous expression of neisserial proteins
US20020086837A1 (en) * 2000-12-21 2002-07-04 Jack Gauldie Acne vaccine
JPWO2002088175A1 (en) * 2001-04-24 2004-08-19 大塚製薬株式会社 Antibody binding peptide for Crohn's disease and method for testing Crohn's disease
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
AU2003205605A1 (en) * 2002-01-18 2003-07-30 Karo Bio Ab Conformation-specific, protein kinase binding peptides and related methods and products
IL165364A0 (en) * 2002-05-28 2006-01-15 Omrix Biopharmaceuticals Inc Method for obtaining anti-idiotype antibodies
AU2003273540A1 (en) * 2002-05-31 2003-12-19 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
DE10232776A1 (en) * 2002-07-18 2004-04-08 Henkel Kgaa New oligonucleotides for specific detection of microorganisms, useful e.g. for detecting or quantifying microbes on the skin, in foods, clinical samples or water, by in situ hybridization
WO2004056853A2 (en) * 2002-12-23 2004-07-08 Vib Vzw An immunomodulatory protein derived from trypanosomes and uses thereof
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
JPWO2005047313A1 (en) * 2003-11-14 2007-11-29 株式会社ペプタイドドア Peptide or protein having binding ability to LipidA and LPS, DNA encoding the peptide or protein, LPS adsorbent or LPS toxicity neutralizing agent using the peptide or protein
AU2005221729B2 (en) * 2004-03-15 2009-09-24 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
CA2559390A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
ATE462719T1 (en) * 2004-07-01 2010-04-15 Biomay Ag HOUSE DUST MITE ALLERGEN
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
ATE538806T1 (en) * 2004-09-07 2012-01-15 Burnham Inst PEPTIDES SPECIFICALLY SITE IN CARDIAC VESSELS AND RELATED CONJUGATES AND METHODS
EP2042186A1 (en) * 2005-01-31 2009-04-01 Vaxinnate Corporation Novel polypeptide ligands for toll-like receptor 2 (TLR2)
DE602006015444D1 (en) * 2005-03-22 2010-08-26 Novozymes As POLYPEPTIDES AND NUCLEIC ACIDS THAT CODE THESE
CA2614800C (en) * 2005-07-12 2018-10-30 The University Of Leeds Bacteriophage specifically for lysing propionibacterium acnes and uses thereof
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
DE602006012515D1 (en) * 2006-12-15 2010-04-08 Giuseppe Campiani Novel taxane-related peptides and their use
WO2009105592A2 (en) * 2008-02-19 2009-08-27 Hogan James J Compositions and methods for detection of propionibacterium acnes nucleic acid
US20110195911A1 (en) * 2008-03-28 2011-08-11 The United States Of America,As Represented By The Secretary,Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
FR2937322B1 (en) 2008-10-22 2013-02-22 Vect Horus PEPTIDE DERIVATIVES AND THEIR USE AS VECTORS OF MOLECULES IN THE FORM OF CONJUGATES
CN106905429A (en) 2008-12-05 2017-06-30 阿布拉西斯生物科学有限责任公司 With reference to the scFv of SPARC
CA2776949A1 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Methods and compositions for treating p.acnes
FR2945125B1 (en) * 2009-05-04 2013-07-19 Ingen Biosciences METHOD OF DIAGNOSING PROPIONIBACTERIUM ACNE INFECTIONS
PL2248533T3 (en) * 2009-05-05 2014-04-30 Univ Freiburg Polypeptide derived from enterococcus and its use for vaccination
FR2959229B1 (en) * 2010-04-21 2013-01-18 Vect Horus PEPTIDE DERIVATIVES, THEIR PREPARATION AND USES THEREOF
RU2012153241A (en) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. ANTIBODIES TO FGFR2
DE11786796T8 (en) * 2010-05-27 2013-04-25 Hasumi Kenichiro ANTIGENPEPTIDE AND USE THEREOF
JP2015512255A (en) 2012-03-17 2015-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Rapid diagnosis and personalized treatment of acne
CA2904960A1 (en) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
WO2015138494A1 (en) 2014-03-10 2015-09-17 Georges Belfort Anti-microbial peptides and method for designing novel anti-microbial peptides
US10584344B2 (en) 2014-06-17 2020-03-10 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
IL292830B2 (en) 2015-09-28 2023-06-01 Univ Florida Methods and compositions for antibody-evading virus vectors
US11155578B2 (en) * 2016-02-17 2021-10-26 Pepticom Ltd. Peptide agonists and antagonists of TLR4 activation
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
JP2019514885A (en) 2016-04-21 2019-06-06 ネイキッド バイオーム，インク． Compositions and methods for the treatment of skin disorders
CN106167820A (en) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 Identify or assist primer special and the application thereof identifying propionibacterium acnes
WO2019067587A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
EP3887386A4 (en) * 2018-11-26 2022-11-30 North Carolina State University Peptide ligands for capture of host cell proteins
AR118465A1 (en) 2019-03-21 2021-10-06 Stridebio Inc RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
MX2022004352A (en) 2019-10-17 2022-07-19 Stridebio Inc Adeno-associated viral vectors for treatment of niemann-pick disease type c.
CA3161901A1 (en) * 2019-12-20 2021-06-24 Shane Stone Novel cellular delivery methods
AU2021223787A1 (en) 2020-02-21 2022-10-13 Sanofi Foreign Participations BV Propionibacterium acnes prophylactic and therapeutic immune treatment
EP4149511A4 (en) * 2020-05-15 2024-05-22 Univ Southern California Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer
KR20230083100A (en) * 2021-12-02 2023-06-09 삼성전자주식회사 Polypetide, photoresist composition including the same and method of forming pattern using the same

Also Published As

Publication number Publication date
WO2001081581A9 (en) 2003-01-03
EP1278854A2 (en) 2003-01-29
CA2407352A1 (en) 2001-11-01
WO2001081581A3 (en) 2002-03-14
WO2001081581A2 (en) 2001-11-01
JP2004520803A (en) 2004-07-15

Similar Documents

Publication Publication Date Title
AU2001255524A1 (en) Compositions and methods for the therapy and diagnosis of acne vulgaris
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer